Login to Your Account

Aranesp, Enbrel, Neulasta Sales Drive Amgen To Beat Estimates

By Aaron Lorenzo

Monday, July 26, 2004
Amgen Inc. turned in second-quarter adjusted earnings per share of 62 cents, topping consensus estimates and surging 27 percent higher than a year ago. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription